Skip to content

Intraoperative CO₂ (Carbon Dioxide)

Intraoperative Fractionated CO₂ Laser Treatment of Wound Edges During Mohs Micrographic Surgery

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07592468
Enrollment
50
Registered
2026-05-18
Start date
2026-05-01
Completion date
2027-12-01
Last updated
2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound Edges

Brief summary

To evaluate whether intraoperative fractionated CO₂ laser treatment of surgical wound edges improves postoperative scar appearance compared with untreated wound edges following Mohs micrographic surgery (MMS).

Detailed description

This is a randomized, split-scar clinical study. After patients undergo the MMS surgery and before the wound is closed one half of the wound edge will be treated with a CO2 laser and the other half will be untreated. The side of the would receiving the laser treatment will be determined by random assignment. The study aims to evaluate if the wound edge that is laser treated will have an improved scar appearance compared to the non-laser treated wound edge.

Interventions

DEVICECO2 Fractionated Laser

intraoperative fractionated CO₂ laser treatment of surgical wound edges

PROCEDURENon CO2 Laser Treatment

Untreated CO2 fractionated laser wound edges

Sponsors

Baylor Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Adults aged 18-89 years * Diagnosis of cutaneous malignancy treated with MMS * Surgical defect suitable for primary linear or flap closure with adequate length to permit split-scar design * Ability to understand and provide informed consent

Exclusion criteria

* Pregnancy * Inability to provide informed consent * Non-English speaking patients * History of abnormal wound healing (e.g., keloid disorder) * Active infection at the surgical site * Immunosuppression felt to significantly impair wound healing * Use of isotretinoin within the past 6 months * Prior radiation therapy to the surgical site * Patients belonging to vulnerable populations including prisoners, children, or individuals unable to consent

Design outcomes

Primary

MeasureTime frameDescription
Improvement of postoperative scar appearance3 monthsTo evaluate whether intraoperative fractionated CO₂ laser treatment of surgical wound edges improves postoperative scar appearance compared with untreated wound edges following Mohs micrographic surgery. Evaluating the perspective of the scar from both the patient and medical professional using the Patient and Observer Scar Assessment Scale (POSAS), which evaluates scar quality. Using a scale of 1-10, where 1 is "like normal skin" and 10 is the "worst imaginable and using verbal feedback from patients about the appearance of their scars.

Secondary

MeasureTime frameDescription
Scar Appearance3 monthsTo assess patients overall satisfaction with scar appearance. This will be done verbally with patients stating they are "satisfied, somewhat satisfied, or not satisfied".
Physician Scar Assessments3 monthsA group of blinded medical professionals will assess the treated and untreated scar using several standardized assessments. The first is the Patient and Observer Scar Assessment Scale (POSAS), which evaluates scar quality. Using a scale of 1-10, where 1 is "like normal skin" and 10 is the "worst imaginable. The second is the Vancouver Scar Scale (VSS). This scale evaluates scars across 4 physical characteristics using a score range of 0-13, where 0 represents normal skin and 13 represents the most severe scarring. Finally the third assessment is the Global Aesthetic Improvement Scale (GAIS). This scale looks at how much better the patient looks compared to pre-surgery. This scale uses a scoring range of 1-5, where 1 represents exceptional improvement and 5 represents worse.
Clinical Safety and Healing Outcomes.1 week, 1 month, 3 monthsTo evaluate the safety of intraoperative fractionated CO₂ laser treatment, including healing time and complication rates. During the follow up visits the physician will do conduct a visual assessment for presence of any infection, dehiscence, poor wound healing. The physician will use a global assessment of 1-5 and the formal Patient and Observer Scar Assessment Scale (POSAS), which evaluates scar quality. Using a scale of 1-10, where 1 is "like normal skin" and 10 is the "worst imaginable.

Countries

United States

Contacts

CONTACTUmer Nadir, MD
umer.nadir@bswhealth.org214-820-2361
PRINCIPAL_INVESTIGATORStan Tolkachjov, MD

Baylor Health Care System

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026